Replies to post #226275 on Biotech Values

[DewDiligence]

ICPT 3Q19 results:

http://ir.interceptpharma.com/news-releases/news-release-details/intercept-pharmaceuticals-reports-third-quarter-2019-financial

ICPT raised full-year 2019 Ocaliva sales guidance (for PBC indication only) to $245-250M (from the prior range of $235-245M).

CC slides:
http://ir.interceptpharma.com/static-files/45a2334a-a7ae-4416-bb79-052be89a326e

[DewDiligence]

ICPT PDUFA for NASH is 3/26/20 (with priority review):

https://www.globenewswire.com/news-release/2019/11/25/1951936/0/en/FDA-Accepts-Intercept-s-NDA-for-OCA-for-the-Treatment-of-Liver-Fibrosis-Due-to-NASH-and-Grants-Priority-Review.html